Clinical Trial Update: Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC [Phase 2]

View source ↗

Summary

Phase 2 study of ENMD-2076, an Aurora and angiogenic kinase inhibitor, in previously treated locally advanced or metastatic triple-negative breast cancer has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ENMD-2076 (ENMD-2076)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED